Myovant Sciences completes patient recruitment for phase 3 SPIRIT 2 study
Myovant Sciences announced it has completed patient recruitment for its SPIRIT 2 study, the first of two Phase 3 replicate studies evaluating relugolix combination therapy in women with endometriosis-associated pain. The SPIRIT 2 study is part of an international clinical development program. August 20, 2019